Clinical Trials Logo

Clinical Trial Summary

This phase IV trial examines the effectiveness of a multi-level smoking cessation program for high-risk women in rural communities. Cigarette smoking is a major risk factor for cervical cancer in women. Rural primary care practices and providers often lack the electronic health record support to pre-identify smokers for services, as well as lack the necessary counseling training and access to comprehensive cessation programs. Implementing evidence-based smoking cessation programs in rural Appalachia may decrease the rates of cigarette smoking and as a result decrease the rates of cervical cancer.


Clinical Trial Description

PRIMARY OBJECTIVES: I. Determine the effectiveness of a core component of an integrated cervical cancer prevention program designed to help female smokers quit by standardizing clinical practice supports and protocols. (Service outcomes) II. Determine satisfaction with the multilevel intervention. (Client outcomes) III. Test the sustainability of the multilevel intervention via training of providers and staff on counseling and billing for evidence-based smoking cessation services. (Implementation outcomes) OUTLINE: IMPLEMENTATION OF TOBACCO-USER IDENTIFICATION SYSTEM: Clinics and systems develop and implement minimally required electronic tracking and reporting systems for identification of smokers during months 1-12. GROUP RANDOMIZED TRIAL: Providers and participants are randomized to 1 of 2 arms. ARM I (EARLY ARM): Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 13-24. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist. ARM II (DELAYED ARM): Female smokers receive usual care during months 13-24. Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 25-36. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04340531
Study type Interventional
Source Ohio State University Comprehensive Cancer Center
Contact Ohio State Comprehensive Cancer Center
Phone 800-293-5066
Email OSUCCCClinicaltrials@osumc.edu
Status Recruiting
Phase Phase 4
Start date January 30, 2021
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06315881 - Informing Oral Nicotine Pouch Regulations to Promote Public Health Phase 2
Active, not recruiting NCT02964182 - Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers N/A
Completed NCT04267874 - Black Raspberry Nectar for the Prevention of Lung Cancer, BE WELL Study Early Phase 1
Completed NCT04510077 - SmartQuit Program for Smoking Cessation N/A
Completed NCT03200236 - The Lung Screening, Tobacco and Health Project Phase 3
Recruiting NCT06448351 - Manipulating E-Cigarette Nicotine to Promote Public Health N/A
Recruiting NCT05730439 - Examining the Impact of Nicotine Pouches in Rural Ohio and Ohio Appalachia Early Phase 1
Recruiting NCT04949464 - Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study N/A
Not yet recruiting NCT06249984 - Effects of Tobacco Cut and Nicotine Form on the Abuse Liability of Moist Snuff N/A
Enrolling by invitation NCT04969978 - Electronic Quitline Referral With Enhanced Academic Detailing for the Promotion of Smoking Cessation N/A
Completed NCT05972941 - Nicotine and Tobacco Message Framing Among LGBT Young Adults N/A
Completed NCT05453773 - Hookah Additive Research to Inform Product Standards N/A
Withdrawn NCT05411107 - Oral Iloprost for the Prevention of Lung Cancer In Former Smokers Phase 2
Completed NCT03268993 - Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer N/A
Terminated NCT04297332 - Episodic Future Thinking and Future Thinking Priming for Smoking Cessation N/A
Completed NCT03402230 - Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers Early Phase 1
Recruiting NCT05876091 - Effects of Tobacco Flavoring and Liquid Composition on Vaping Topography N/A
Completed NCT03182959 - Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer Early Phase 1
Completed NCT05393869 - Evaluating Anti-Tobacco Message Effectiveness Among Lesbian, Gay, Bisexual, and Transgender Young Adults N/A
Recruiting NCT05679349 - Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking N/A